Brii Biosciences

Explore the latest insights on Brii Biosciences and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Brii Biosciences’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Explore the latest insights on Brii Biosciences and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Brii Biosciences's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Lifetech's ICS Elpis Bioresorbable Peripheral Stent Enters NMPA Green Channel – World's First Fully Bioresorbable Covered Stent System for Iliac Artery Disease
CompanyMedical Device

Lifetech’s ICS Elpis Bioresorbable Peripheral Stent Enters NMPA Green Channel – World’s First Fully Bioresorbable Covered Stent System for Iliac Artery Disease

Lifetech Scientific Corporation (HKG: 1302) announced that the ICS Elpis Bioresorbable Peripheral Balloon‑Expandable Covered Stent System, independently developed by its subsidiary Yuanxin Technology (Shenzhen) Co., Ltd., was approved for entry…

GE HealthCare Launches Global Clinical Evaluation of StarGuide GXi – Next‑Generation Digital 4D SPECT/CT Spans Three Continents and Five Elite Institutions

GE HealthCare Launches Global Clinical Evaluation of StarGuide GXi – Next‑Generation Digital 4D SPECT/CT Spans Three Continents and Five Elite Institutions

Sisram Medical's Profhilo Facial Registration Accepted by NMPA – BDDE‑Free Hyaluronic Acid Biostimulator Poised for China's Aesthetics Market

Sisram Medical’s Profhilo Facial Registration Accepted by NMPA – BDDE‑Free Hyaluronic Acid Biostimulator Poised for China’s Aesthetics Market

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases
CompanyR&D

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases

CompanyDrug

Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B

Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery
CompanyDeals

Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery

Brii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China
CompanyDeals

Brii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China

Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting
CompanyDrug

Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting

Brii Biosciences to Acquire Full Rights to BRII-179 from VBI Vaccines
CompanyDeals

Brii Biosciences to Acquire Full Rights to BRII-179 from VBI Vaccines

Brii Biosciences' Elebsiran Shows Promising Results in Phase II ENSURE Study for Chronic HBV
CompanyDrug

Brii Biosciences’ Elebsiran Shows Promising Results in Phase II ENSURE Study for Chronic HBV

Company

Brii Bioscience’s US Partner VBI Vaccines Initiates Bankruptcy Reorganization

Show More